Special BD LSR Fortessa

描述（由申请人提供）：威斯康星大学卡本癌症中心（UWCCC）流式细胞术实验室（Flow Lab）是威斯康星大学麦迪逊分校校园内一个被大量利用的共享服务，向UWCCC的成员和非成员的研究人员开放。流动实验室对威斯康星大学麦迪逊分校生物医学研究基础设施的影响是显著的。这项共享仪器补助金是一项资金申请，用于支付BD LSR Fortessa”（Fortessa）仪器总成本的80%（其余20%由机构支持），以进一步提高Flow实验室的能力和容量。Fortessa的加入将减轻我们的用户目前所经历的2-3周的等待时间，允许及时分析临床研究样本。它将提供高激光功率，以提高细胞亚群的分辨率和检测新开发的荧光标记所需的激发波长（561nm和355nm），并将包括一个高通量采样器选项，以提高效率和筛选能力。当现有的5激光LSR正在进行维护和/或维修时，该仪器将提供冗余。经验丰富的员工，完善的日常质量控制程序，在线调度系统和教育计划允许无缝整合Fortessa到流动实验室。Fortessa细胞仪将影响各种人类病理的新治疗策略的发展，并增加我们对人类生物学的理解。受益于增加Fortessa的主要和次要用户资助的项目包括：(i)开发前列腺癌疫苗的临床试验（Doug McNeel）， （ii）黑色素瘤免疫治疗剂（Paul Sondel）， （iii） CMML小鼠模型（Jing Zhang）， （iv）乳腺癌遗传调节大鼠模型（Michael Gould）， (v)调节卵巢癌免疫反应（Manish Patankar），（vi）同种异体骨髓移植伴恶性血液肿瘤患者的移植物抗宿主病，（vii）生物行为因素对免疫功能的影响（Erin Costanzo）， （viii）肾脏疾病中的纤维生成（Arjung Djamali）， （ix）造血干细胞成熟为心肌细胞（Sean Palecek）， (x)炎症对神经细胞的影响导致的通气控制（Jyoti Watters），（xi）锌转运体基因突变对Ehlers- Danlos综合征sphodylocheiro发育不良形式的影响（David Eide）， （xii）农场和非农场抚养儿童的免疫成熟和调节，以更好地了解哮鸣疾病（David Gern）， （xiii）肿瘤抑制和DNA损伤中的转录因子（Randall Tibbets），以及（xiv）抗真菌疫苗的开发（Marcel W¿thrich和Bruce Klein）。优秀的机构支持形式为总价的20%成本分担

DESCRIPTION (provided by applicant): The University of Wisconsin Carbone Cancer Center (UWCCC) Flow Cytometry Laboratory (Flow Lab) is a heavily utilized shared service on the University of Wisconsin-Madison campus available to researchers who are members as well as non-members of the UWCCC. The impact of the Flow Lab on biomedical research infrastructure at UW-Madison is significant. This Shared Instrumentation Grant is a request for funds that cover 80% (remaining 20% supported by the institution) of the total cost of a BD LSR Fortessa" (Fortessa) instrument to further enhance the capability and the capacity of the Flow Lab. The addition of the Fortessa will alleviate the 2-3 week wait times currently experienced by our users allowing timely analysis of clinical research samples. It will provide high laser power for increased resolution of cellular subpopulations and excitation wavelengths (561nm and 355nm) necessary for detection of newly developed fluorescent markers, and will include a High-Throughput Sampler option for increased efficiency and screening capability. This instrument will provide redundancy when the existing 5-laser LSR is undergoing maintenance and/or repair. The experienced staff, well-established daily Quality Control Procedures, Online Scheduling System and Educational Programs allow for seamless integration of the Fortessa into the Flow Lab. The Fortessa cytometer will impact the development of novel treatment strategies for various human pathologies and increase our understanding of human biology. Funded projects by major and minor users benefiting by addition of the Fortessa include (i) clinical trials for development of a prostate cancer vaccine (Doug McNeel), (ii) immunotherapeutic agents for melanoma (Paul Sondel), (iii) mouse models for CMML (Jing Zhang), (iv) rat models for genetic modulation of mammary cancer (Michael Gould), (v) modulating immune responses in ovarian cancer (Manish Patankar), (vi) Graft versus Host disease in allogeneic bone marrow transplant patients with hematologic malignancies, (vii) effect of biobehavioral factors on immune function (Erin Costanzo), (viii) fibrogenesis in kidney disease (Arjung Djamali), (ix) hematopoietic stem cell maturation into cardiomyocytes (Sean Palecek), (x) ventilatory control due to effects of inflammation on neuronal cells (Jyoti Watters), (xi) effect of genetic mutations in a zinc transporter on sphodylocheiro dysplastic form of Ehlers- Danlos Syndrome (David Eide), (xii) immune maturation and regulation in farm and non-farm raised children to better understand wheezing illnesses (David Gern), (xiii) transcription factors in tumor suppression and DNA damage (Randall Tibbets), and (xiv) development of anti-fungal vaccines (Marcel W¿thrich and Bruce Klein). Excellent institutional support in the form of 20% cost sharing of the total price of the Fortessa, salary support for trained technical staff, and the service agreement to maintain a fully functional and well-equipped cytometer will allow us to fulfill the research needs of major and minor users for the next 10 years.